Molecular imaging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently used in the staging of prostate cancer, for the assessment of biochemical recurrence after therapy, as well as for planning for radiopharmaceutical treatment targeting PSMA. This evidence concerns the gene FOLH1 and Familial prostate cancer.